National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, Ireland.
Department of Nephrology, Children's University Hospital, Temple Street, Dublin 1, Ireland.
J Nephrol. 2018 Jun;31(3):445-451. doi: 10.1007/s40620-017-0462-2. Epub 2017 Nov 28.
Epstein-Barr virus (EBV) was the first human virus identified to express microRNA (miRNA). To date, 44 mature miRNAs are encoded for within the EBV genome. EBV miRNAs have not been profiled in paediatric renal transplant recipients. In this study, we investigated circulating EBV miRNA profiles as novel biomarkers in paediatric renal transplant patients.
Forty-two microRNAs encoded within 2 EBV open reading frames (BART and BHRF) were examined in renal transplant recipients who resolved EBV infection (REI) or maintained chronic high viral loads (CHL), and in non-transplant patients with acute infectious mononucleosis (IM).
Plasma EBV-miR-BART2-5p was present in higher numbers of IM (7/8) and CHL (7/10) compared to REI (7/12) patients. A trend was observed between the numbers of plasma EBV miRNAs expressed and EBV viral load (p < 0.07). Several EBV-miRs including BART7-3p, 15, 9-3p, 11-3p, 1-3p and 3-3p were detected in IM and CHL patients only. The lytic EBV-miRs, BHRF1-2-3p and 1-1, indicating active viral replication, were detected in IM patients only. One CHL patient developed post-transplant lymphoproliferative disease (PTLD) after several years and analysis of 10 samples over a 30-month period showed an average 24-fold higher change in plasma EBV-miR-BART2-5p compared to the CHL group and 110-fold higher change compared to the REI group.
Our results suggest that EBV-miR-BART2-5p, which targets the stress-induced immune ligand MICB to escape recognition and elimination by NK cells, may have a role in sustaining high EBV viral loads in CHL paediatric kidney transplant recipients.
爱泼斯坦-巴尔病毒(EBV)是第一个被鉴定出表达微小 RNA(miRNA)的人类病毒。迄今为止,EBV 基因组中编码了 44 个成熟的 miRNA。EBV miRNA 尚未在儿科肾移植受者中进行分析。在这项研究中,我们研究了循环 EBV miRNA 谱作为儿科肾移植患者的新型生物标志物。
在解决 EBV 感染(REI)或维持慢性高病毒载量(CHL)的肾移植受者以及患有急性传染性单核细胞增多症(IM)的非移植患者中,检查了 EBV 两个开放阅读框(BART 和 BHRF)内编码的 42 个 miRNA。
与 REI(7/12)患者相比,IM(7/8)和 CHL(7/10)患者血浆 EBV-miR-BART2-5p 的数量更多。观察到表达的血浆 EBV miRNA 数量与 EBV 病毒载量之间存在趋势(p<0.07)。在 IM 和 CHL 患者中仅检测到几种 EBV-miRs,包括 BART7-3p、15、9-3p、11-3p、1-3p 和 3-3p。指示病毒复制活跃的裂解 EBV-miRs,BHRF1-2-3p 和 1-1,仅在 IM 患者中检测到。一名 CHL 患者在数年后发生移植后淋巴组织增生性疾病(PTLD),对 30 个月期间的 10 个样本进行分析显示,与 CHL 组相比,血浆 EBV-miR-BART2-5p 的平均变化增加了 24 倍,与 REI 组相比增加了 110 倍。
我们的结果表明,EBV-miR-BART2-5p 可能在维持 CHL 儿科肾移植受者的 EBV 高病毒载量中起作用,该 miRNA 靶向应激诱导的免疫配体 MICB,以逃避 NK 细胞的识别和消除。